secwatch.observer — SEC 8-K summary
======================================

Issuer:     Journey Medical Corp (DERM)
CIK:        0001867066
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001104659-22-117116
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Journey Medical Q3 revenue down 18% to $16.1M; net loss $10.1M; DFD-29 Phase 3 75% enrolled
--------------------------------------------------------------------------------

- Revenue $16.1M in Q3 2022 versus $19.6M in Q3 2021, decline due to Targadox generic competition.
- Net loss $10.1M ($0.57/sh) vs $10.6M ($1.16/sh); Non-GAAP Adj EBITDA loss $4.0M vs +$1.3M.
- DFD-29 Phase 3 studies 75% enrolled; top-line data expected H1 2023, NDA filing H2 2023.
- Nine-month revenue up 26% to $57.7M; CEO expects record full-year 2022 revenue.
- Company expects to launch another product in the upcoming months.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1867066/000110465922117116/0001104659-22-117116-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1867066/000110465922117116/tm2230077d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-117116

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer